ESMO Press Releases

If you require further information regarding any of the press releases listed below, please do not hesitate to contact us (select 'Press & Media').

Filter

Date Title Topic
07 Dec 2016 ESMO Asia 2016 Press Release: Patients Wait Four Months Before Seeking Cancer Diagnosis
23 Nov 2016 Media Alert: Catch Up on Cancer News at ESMO Asia 2016
08 Nov 2016 Media Alert: ESMO Asia 2016 – Cancer Experts Meet in Singapore from 16 to 19 December 2016
28 Oct 2016 Media Alert: ESMO Symposium on Immuno-Oncology 2016 Cancer Immunology and Immunotherapy
11 Oct 2016 ESMO 2016 Press Release: Best of ESMO 2016 Congress
10 Oct 2016 ESMO 2016 Press Release: Longer Disease-free Survival in Phase III Trial of Sunitinib as Adjuvant Treatment for Kidney Cancer Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: Single-Arm Trials Improve Early Access to Rare Cancer Drugs Translational research
10 Oct 2016 ESMO 2016 Press Release: Financial Difficulties Linked to Worse Outcomes From Cancer Treatment Bioethics, legal and economic issues
10 Oct 2016 ESMO 2016 Press Release: Cabozantinib Improves Progression-free Survival in Metastatic Renal Cell Carcinoma Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: MEK Inhibition in KRAS-mutant NSCLC Did Not Improve Survival Lung and other thoracic tumours
10 Oct 2016 ESMO 2016 Press Release: Significant Survival Gains from Neoadjuvant Chemotherapy for High-risk Soft Tissue Sarcoma Sarcomas
10 Oct 2016 ESMO 2016 Press Release: Custirsen Shows no Survival Benefits in Metastatic Prostate Cancer Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: First Feasibility Study of the ESMO-MCBS Scale in Rare Tumour Entities Bioethics, legal and economic issues
09 Oct 2016 ESMO 2016 Press Release: Greater Patient Selection May be Needed for First Line Nivolumab to Improve Progression-free Survival in Advanced Lung Cancer Lung and other thoracic tumours
09 Oct 2016 ESMO 2016 Press Release: Ceritinib Provides Longer Progression-free Survival Than Chemotherapy in Phase III Trial of ALK Rearranged Lung Cancer Treatment Lung and other thoracic tumours